Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada.
about
A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemiaManufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacyII Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy.
P2860
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Implications to payers of swit ...... immunodeficiencies in Canada.
@ast
Implications to payers of swit ...... immunodeficiencies in Canada.
@en
type
label
Implications to payers of swit ...... immunodeficiencies in Canada.
@ast
Implications to payers of swit ...... immunodeficiencies in Canada.
@en
prefLabel
Implications to payers of swit ...... immunodeficiencies in Canada.
@ast
Implications to payers of swit ...... immunodeficiencies in Canada.
@en
P2860
P356
P1476
Implications to payers of swit ...... immunodeficiencies in Canada.
@en
P2093
Arthur S Zbrozek
William C Gerth
P2860
P2888
P356
10.1186/1710-1492-10-23
P577
2014-05-07T00:00:00Z
P5875
P6179
1017069741